Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis

被引:45
|
作者
Cadour, Farah [1 ]
Cautela, Jennifer [2 ]
Rapacchi, Stanislas [3 ]
Varoquaux, Arthur [4 ]
Habert, Paul [1 ]
Arnaud, Francois [1 ]
Jacquier, Alexis [1 ]
Meilhac, Alexandra [2 ]
Paganelli, Franck [2 ]
Lalevee, Nathalie [2 ]
Scemama, Ugo [5 ]
Thuny, Franck [2 ]
机构
[1] Aix Marseille Univ, Dept Radiol, La Timone Hosp, AP HM, Marseille, France
[2] Aix Marseille Univ, Univ Mediterranean Ctr Cardiooncol,Inrae 1260, Unit Heart Failure & Valvular Heart Dis,Inserm 12, Dept Cardiol,North Hosp,AP HM,Ctr Cardiovasc & Nu, Chemin Bourrely, F-13015 Marseille, France
[3] Aix Marseille Univ, CEMEREM, La Timone Hosp, AP HM,CNRS,CRMBM, Marseille, France
[4] Aix Marseille Univ, Dept Radiol, La Conception Hosp, AP HM, F-13005 Marseille, France
[5] St Joseph Hosp, Dept Radiol, Marseille, France
关键词
CARDIOVASCULAR MAGNETIC-RESONANCE; LATE GADOLINIUM ENHANCEMENT; ENDOMYOCARDIAL BIOPSY; EUROPEAN-SOCIETY; MANAGEMENT; ASSOCIATION; STATEMENT; CARDIOLOGY; RISK;
D O I
10.1148/radiol.211765
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Cardiac MRI features are not well-defined in immune checkpoint inhibitor (ICI)-induced myocarditis (ICI-M), a severe complication of ICI therapy in patients with cancer. Purpose: To analyze the cardiac MRI features of ICI-M and to explore their prognostic value in major adverse cardiovascular events (MACE). Materials and Methods: In this retrospective study from May 2017 to January 2020, cardiac MRI findings (including late gadolinium enhancement [LGE], T1 and T2 mapping, and extracellular volume fraction [ECV] z scores) of patients with ICI-M were compared with those of patients with cancer scheduled to receive ICI therapy (pre-ICI group) and patients with viral myocarditis. As a secondary objective, the potential value of cardiac MRI for predicting MACE in patients with ICI-M by using Cox proportional hazards models was explored. Results: Thirty-three patients with ICI-M (mean age +/- standard deviation, 68 years +/- 14; 23 men) were compared with 21 patients scheduled to receive to ICI therapy (mean age, 65 years +/- 14; 14 men) and 85 patients with viral myocarditis (mean age, 32 years +/- 13; 67 men). Compared with the pre-ICI group, patients with ICI-M showed higher global native T1, ECV, and T2 z scores (0.03 +/- 0.85 vs 1.79 +/- 1.93 [P < .001]; 1.34 +/- 0.57 vs 2.59 +/- 1.97 [P = .03]; and -0.76 +/- 1.41 vs 0.88 +/- 1.96 [P = .002], respectively), and LGE was more frequently observed (27 of 33 patients [82%] vs two of 21 [10%]; P < .001). LGE was less frequent in patients with ICI-M than those with viral myocarditis (27 of 33 patients [82%] vs 85 of 85 [100%]; P < .001) but was more likely to involve the septal segments (16 of 33 patients [48%] vs 25 of 85 [29%]; P < .001) and midwall layer (11 of 33 patients [33%] vs two of 85 [2%]; P < .001). Septal LGE was the only cardiac MRI predictor of MACE at 1 year even after adjustment for peak troponin (adjusted hazard ratio, 2.7 [95% CI: 1.1, 6.7]; P = .03). Conclusion: Cardiac MRI features of immune checkpoint inhibitor (ICI)-induced myocarditis (ICI-M) seem to differ from those in patients scheduled to receive ICIs and patients with viral myocarditis. Septal late gadolinium enhancement might be a predictor of major cardiovascular events in patients with ICI-M. (C) RSNA, 2022
引用
收藏
页码:512 / 521
页数:10
相关论文
共 50 条
  • [1] Cardiovascular Magnetic Resonance Imaging Features and Prognostic Value in Immune Checkpoint Inhibitor-Induced Myocarditis
    Cadour, Farah
    Cautela, Jennifer
    Rapacchi, Stanislas
    Varoquax, Arthur
    Habert, Paul
    Arnaud, Francois
    Jacquier, Alexis
    Meilhac, Alexandra
    Paganelli, Franck
    Lalevee, Natalie
    Scemama, Ugo
    Thuny, Franck
    CIRCULATION, 2021, 144
  • [2] Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study
    Faron, Anton
    Isaak, Alexander
    Mesropyan, Narine
    Reinert, Matthaeus
    Schwab, Katjana
    Sirokay, Judith
    Sprinkart, Alois M.
    Bauernfeind, Franz-Georg
    Dabir, Darius
    Pieper, Claus C.
    Heine, Annkristin
    Kuetting, Daniel
    Attenberger, Ulrike
    Landsberg, Jennifer
    Luetkens, Julian A.
    RADIOLOGY, 2021, 301 (03) : 602 - 609
  • [3] Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
    Jimenez-Alejandre, Rosa
    Ruiz-Fernandez, Ignacio
    Martin, Pilar
    CANCERS, 2022, 14 (18)
  • [4] IMMUNE CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS: A TRUE DILEMMA
    Cao, Kevin
    Parekh, Mansi
    Dewaswala, Nakeya
    Bhopalwala, Huzefa
    Arbune, Amit
    CHEST, 2023, 164 (04) : 293A - 293A
  • [5] Plasma Exchange for Immune Checkpoint Inhibitor-Induced Myocarditis
    Yogasundaram, Haran
    Alhumaid, Waleed
    Chen, June W.
    Church, Matthew
    Alhulaimi, Naji
    Kimber, Shane
    Paterson, Ian
    Senaratne, Janek M.
    CJC OPEN, 2021, 3 (03) : 379 - 382
  • [6] Checkpoint inhibitor-induced myocarditis
    Gulati, Geeta
    Tjessem, Kristin Holm
    Horndalsveen, Henrik
    Halvorsen, Sigrun
    Haakensen, Vilde Drageset
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2022, 142 (18) : 1562 - 1566
  • [7] Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis
    Kuniyoshi, Jason
    Huang, Ricky
    Choi, Horyun
    Bernas, Monika
    Techasatian, Witina
    Nishimura, Yoshito
    CANADIAN JOURNAL OF CARDIOLOGY, 2023, 39 (11) : 1646 - 1648
  • [8] Overcoming challenges of immune checkpoint inhibitor-induced myocarditis diagnosis
    Cautela, Jennifer
    Deharo, Francois
    Thuny, Franck
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2023, 116 (10) : 429 - 432
  • [9] Biomarkers for Immune Checkpoint Inhibitor-Induced Myocarditis Caution Needed
    Jaffe, Allan S.
    JACC: CARDIOONCOLOGY, 2022, 4 (05): : 701 - 703
  • [10] A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response
    Hassan, Mubariz A.
    Batta, Yashvardhan
    Afzal, Muhammad Adil
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)